Objectives:

• Explore the relationships between T2D and CVD and CVD risk factors
• Discuss definitions of primary and secondary prevention of CVD
• Understand lipid and triglyceride management (statins, icosapent ethyl, oral antiplatelet therapy)
• Primary and secondary prevention in type 2 diabetes including long-term oral anti-platelet trials in secondary prevention in T2D

BIO

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.